Abstract
Purpose: To assess the efficacy and safety of dupilumab combined with cyclosporine A in patients with atopic dermatitis.Methods: This retrospective study enrolled 100 patients with atopic dermatitis who received treatment at Beijing Luhe Hospital between November 2020 and November 2022. The patients were randomly divided into two groups, namely, treatment group and comparison group, with 50 cases in each group. Comparison group received cyclosporine A, while the treatment group received dupilumab in addition to cyclosporine A. The various fficacy scores and adverse reactions between the two groups were recorded and compared.Results: After treatment, skin lesion area and severity, EASI score, NRS score, SCORAD score, POEM score and DLQI score in the treatment group were significantly lower than those in the comparison group (p < 0.05).Conclusion: The combination of dupilumab and cyclosporine A significantly alleviates the symptoms of acne and pruritis, as well as reduce the area of skin lesions in patients with atopic dermatitis. This treatment also enhances the quality of life of the patients. However, further but larger clinical trials are required prior to adoption of this combination treatment in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
